AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00535886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natural Trans FA
Description: VA as 6% of total energy
Study NCT00535886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oleic Acid
Description: OA as 6% of total energy
Study NCT02084329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weighted Compression Vest
Study NCT03826446 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: laparoscopic and open complete mesocolic excision with central vascular ligation in right colon cancer.
Study NCT04700592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gabapentin versus Ketamine
Description: A Comparison of Gabapentin and Ketamine in Acute and Chronic Pain
Study NCT01501812 — intervention group
Intervention type: BEHAVIORAL
Intervention: Generalization pattern
Description: During evaluation a conditioning of a tone (conditioning stimulus) and aversive sound (metal scratch) will conduct (another tone which will be un-conditioning stimulus for control). Generalization patterns will be evaluated, by measuring the differentiation capability between different tones (neutral and aversive) before and after the conditioning, and after extinction phase. The generalization will also be measured by the generalization curve that plotted from displaying tones, different from the original tones, and asked the subject whether the current tone is original or new
Study NCT02128841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Direct Factor Xa Inhibitor
Study NCT00084695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV
Study NCT05283655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy
Description: hypnotherapy
Study NCT00084695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given orally
Study NCT01607580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose glucocorticoid Methylprednisolone
Description: patients receive low-dose glucocorticoid from day 5 post transplant
Study NCT00084695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00084695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00084695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT00084695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Given IV
Study NCT01607580 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: low-dose glucocorticoid Methylprednisolone
Description: patients receive low-dose glucocorticoid from day 5 post transplant
Study NCT01892813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy - Transdermal nicotine patch
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT01892813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy - Transdermal nicotine patch
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT01892813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy - Nicotine gum
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT01892813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy - Nicotine gum
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT01892813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy - Nicotine lozenge
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT01892813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy - Nicotine lozenge
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT01892813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT01892813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT01892813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT01892813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT01892813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT01892813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT01892813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT00084695 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiation therapy two times daily on days -7 to -4.
Study NCT01242293 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ringer lactate - Controls
Description: intravenous hydration at a rate of 125 ml per hour during labor
Study NCT01157793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-hGH
Description: r-hGH at a dose of 0.15-1.00 mg/day administered for 48 weeks by s.c. route
Study NCT01157793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-hGH
Description: Initially no treatment for the first 24 weeks followed by administration of r-hGH at a dose of 0.15 1.00 mg/day for the next 24 weeks, by s.c. route
Study NCT00194441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bedside display of cerebral perfusion pressure information
Description: Continually updating highly visible color coded bar graph bedside computer display of cerebral perfusion pressure
Study NCT00194441 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bedside display of cerebral perfusion pressure information
Description: Continually updating highly visible color coded bar graph bedside computer display of cerebral perfusion pressure
Study NCT01976026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow Diversion
Study NCT01976026 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Best Standard Therapy
Study NCT01735461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: There is a regimen for dietary supplement intake that will be provided to study participants.
Study NCT04563663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posteriorization of the talus.
Description: Three sets of a 30-s grade IV anteroposterior mobilization.
Study NCT03813173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lymph node dissection
Description: The patient was operated under general anesthesia with cervical hyper extension. The affected side or bilateral glandular lobes were resected routinely, which was confirmed as PTC by frozen section. Then one or both central lymph node dissection were separately packed and sent for examination. Scope of lymph node dissection in central carotid region: hyoid bone at the upper border, anonymous artery at the lower border, bilateral common carotid artery at the inner edge, shallow from the superficial layer of deep cervical fascia, deep to the deep layer of deep cervical fascia (anterior fascia). The right recurrent laryngeal nerve (RLN) passes through the central area of the right neck and should be specially protected.
Study NCT03813173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node dissection
Description: The patient was operated under general anesthesia with cervical hyper extension. The affected side or bilateral glandular lobes were resected routinely, which was confirmed as PTC by frozen section. Then one or both central lymph node dissection were separately packed and sent for examination. Scope of lymph node dissection in central carotid region: hyoid bone at the upper border, anonymous artery at the lower border, bilateral common carotid artery at the inner edge, shallow from the superficial layer of deep cervical fascia, deep to the deep layer of deep cervical fascia (anterior fascia). The right recurrent laryngeal nerve (RLN) passes through the central area of the right neck and should be specially protected.
Study NCT03501823 — intervention group
Intervention type: OTHER
Intervention: Photoacoustic tomography
Description: A non-invasive, safe modality that relies on light and sound to generate images.
Study NCT01962610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePCA and Pain keycept intervention
Description: Study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit.
Study NCT00632060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual / Manipulative Therapy (M/MT)
Description: Subjects will receive M/MT twice a week for 4 weeks
Study NCT01357837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: 2 capsules of matching placebo once a day, in the morning, for a total of 28 days
Study NCT01357837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT6005
Description: 2 capsules containing a total of 75 µg GRT6005 once a day, in the morning, for a total of 28 days
Study NCT01357837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT6005
Description: 2 capsules containing a total of 200 µg GRT6005 once a day, in the morning, for a total of 28 days
Study NCT01357837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT6005
Description: 2 capsules containing a total of 400 µg GRT6005 once a day, in the morning, for a total of 28 days
Study NCT00279435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: visilizumab
Study NCT00814554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational strategy
Description: 1.Educational strategy. The strategy is to implement health promotion actions aiming at developing personal skills to adopt healthy behaviors in the field of nutrition and physical activity in conformity with up-to-date recommendations and references. Each adolescent will be provided with about 50 education hours distributed in individual and collective activities in school (15 hours), interventions during courses (20 hours), and outdoors activities (15 hours).
Study NCT00814554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening strategy
Description: 2. Screening strategy. Screening includes measurement of BMI and plotting the growing chart with adolescents, measurement of eating troubles. Screening will be performed by the school medical and nurse team. At risk subjects will be defined according to precise criteria and will be referred to the GP and to obesity networks developed by Health Insurance system where they are provided with specific activities with dieticians, physical activity teachers and psychologists. Subjects with psychological difficulties will be referred for psychological care.
Study NCT00814554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental strategy
Description: 3. Environmental strategy. The strategy is to develop in schools favorable and supportive environments for healthy behaviors targeting the collective catering and physical activity offer and the establishment policy. Especially actions aim at increase fruits and vegetables availability, water consumption, physical activity inside the schools.
Study NCT01361789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: parecoxib, valdecoxib, etoricoxib
Description: 40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery
Study NCT01361789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 8 mg IV
Study NCT01892813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT01892813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination pharmacotherapy - Transdermal nicotine patch + bupropion
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT01892813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination pharmacotherapy - Transdermal nicotine patch + bupropion
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT01892813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco quitline referral
Description: Participants assigned to this condition will receive a referral to their state tobacco quitline. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
Study NCT01892813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored behavioral intervention
Description: Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
Study NCT01892813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol use risk reduction
Description: Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
Study NCT01892813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation for depressive symptoms
Description: Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
Study NCT01892813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral management of postcessation weight gain
Description: Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
Study NCT02191969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk With Ease
Description: A self-directed walking intervention developed by the Arthritis Foundation. The intervention is a workbook that coaches participants through walking regularly at a safe, comfortable pace with the ultimate goal of walking at least 30 minutes a day five days a week.
Study NCT02122939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Study NCT04655339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilateral abdominal Lap-TAP
Description: A total of 30ml of anesthetic (0.25% Bupivacaine HCL), 0.25% Liposomal Bupivacaine (Exparel®) or control will be injected into the transversus abdominis plane bilaterally. A long spinal needle attached to a 30cc syringe with the TAP block solution or control will be used to inject the patient. The needle puncture will be halfway between the subcostal margin and anterior superior iliac spine at the midclavicular line. With laparoscopic guidance, needle will enter through the skin, external oblique and internal oblique. Once the needle is in place, injection of 30 ml on each side will be applied between the internal oblique and transversus abdominis muscle. The injection of bupivacaine into this abdominal wall induces an observable bulge, indicating accuracy of the procedure. These steps will be repeated on the contralateral side of the abdomen. All patients will receive 10 ml bupivacaine 0.25% pre-incision infiltration.
Study NCT02168569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem™ (Artemether-lumefantrine combination)
Description: AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.
Study NCT02168569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coarsucam™ (Amodiaquine-artesunate combination)
Description: AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children \<9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children >18-35kg.
Study NCT04477473 — intervention group
Intervention type: OTHER
Intervention: Questionnaire-based observational study
Description: Questionnaire focusing on practical health care issues regarding respiratory support, health status and perception of the COVID-19 issue:~* Symptom score (related to noninvasive ventilation: NIV)~* Thymic disturbances (score of anxiety and depression)~* Compliance to treatment (assessed via tele-monitoring: routine procedure)
Study NCT02861534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat
Description: 2.5, 5.0, or 10.0 mg orally once daily
Study NCT02861534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for vericiguat
Description: 2.5, 5.0, or 10.0 mg orally once daily
Study NCT02871843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001 dose escalation with TMZ + RT
Description: Dose escalation of RRx-001. Dose levels of 0.5, 1.0, 2.0 and 4.0 mg, once weekly.
Study NCT03863925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target controlled infusion, Schnider model
Description: Target controlled infusion (TCI) is an intravenous drug delivery system estimating pharmacokinetics after input of patient's data, e.g. age, sex, body height, body weight. Schnider model is one of TCI model to deliver Propofol. After target concentration at effect site (e.g. the brain) is keyed in, the computerized infusion pump will calculate dosage of bolus and infusion rate for each individual, and calculated concentration of propofol at plasma and brain will be displayed. The clinicians should evaluate the patient's sedation level in response to calculated propofol concentration and titrate target concentration to achieve desired sedation level.
Study NCT03863925 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bolus injection of Propofol
Description: Bolus intravenous injection is a traditional way to deliver anesthetic, and the dosage and amount of medication is based on clinical experience and patients' response.
Study NCT02570217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HHHFNC
Description: infants receive non-invasive respiratory support by mean of HHHFNC
Study NCT02570217 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP
Description: infants receive non-invasive respiratory support by mean of NCPAP
Study NCT00584831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: toric contact lens
Study NCT00584831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens
Study NCT02871843 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Conformal or intensity-modulated radiotherapy (60 Gy in 2 Gy fractions) given 5 days a week for 30 fractions (about 6 weeks)
Study NCT02871843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose Temozolomide (75 mg/m2)
Description: Oral temozolomide 75 mg/m2 daily for 6 weeks
Study NCT02871843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ Maintenance
Description: TMZ maintenance at 150-200 mg/m2
Study NCT03613506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril 12.5 Mg
Description: Taking captopril 12.5mg b.i.d for two months before radiotherapy.